Pfizer Outlook for Little Growth Falls Short of Expectations

Updated on
  • Q4 boosted by new cancer drug Ibrance and vaccine Prevnar
  • 2016 guidance shows earnings and sales not posting much growth

Pfizer Tops Earnings Estimates

Pfizer Inc.said that 2016 earnings and sales may be flat compared to last year, suggesting the drugmaker may continue with its struggle to return to growth after five years of revenue declines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.